Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01032122 | Rituximab in Metastatic Melanoma | terminated | Phase 1 | 9 | Medical University of ViennaOTHER | 1 | Apr 25, 2013 | clinicaltrials |
| NCT00112216 | Immunotherapy of Melanoma Patients | completed | Phase 1 | 9 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00112229 |
| Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients |
| completed |
| Phase 1 |
| 29 |
| Centre Hospitalier Universitaire VaudoisOTHER |
| 1 |
| Apr 22, 2013 |
| clinicaltrials |
| NCT00004184 | Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 50 | University of Alabama at BirminghamOTHER | 0 | Apr 12, 2013 | clinicaltrials |
| NCT00085423 | Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00087386 | Tanespimycin in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00568048 | Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 62 | Swiss Cancer InstituteOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00238329 | PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 2 | 32 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 8, 2013 | clinicaltrials |
| NCT00004022 | Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01340729 | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00091143 | Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | completed | Phase 1 | 20 | Providence Cancer Center, Earle A. Chiles Research InstituteOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00014092 | Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery | completed | Phase 2 | — | Saint Francis HospitalOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00003229 | Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | completed | Phase 1 / Phase 2 | — | Duke UniversityOTHER | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00004244 | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00104845 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2013 | clinicaltrials |
| NCT01416844 | Study of Immune Responses in Patients With Metastatic Melanoma | withdrawn | Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00288041 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00512889 | Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | completed | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2013 | clinicaltrials |
| NCT00003665 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00002754 | Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors | completed | Phase 1 | 6 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00004148 | Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00005961 | O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00017316 | Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003556 | Vaccine Therapy in Treating Patients With Melanoma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00030615 | Decitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01782508 | A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00003911 | S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 31, 2013 | clinicaltrials |
| NCT01216787 | RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00006243 | Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma | completed | N/A | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00036764 | BMS-247550 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00006003 | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00072345 | Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00072163 | Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00004152 | PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00004250 | Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00005949 | Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00024011 | PS-341 in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00204516 | Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens | completed | Phase 1 / Phase 2 | 31 | University Hospital TuebingenOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00204594 | Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28 | completed | Phase 1 / Phase 2 | 1 | University Hospital TuebingenOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00119249 | Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00509496 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00970996 | Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma(BCAA) | completed | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 3, 2013 | clinicaltrials |
| NCT00509288 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00001832 | Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | completed | Phase 2 | 170 | National Cancer Institute (NCI)NIH | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00003802 | Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma | completed | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT00348088 | Melanoma Biomarker Study | completed | — | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00085579 | Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00627419 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | terminated | Phase 2 | 1 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 10, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2013source: clinicaltrials